Clementia Pharmaceuticals Inc (CMTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Clementia Pharmaceuticals Inc (CMTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8303
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Clementia Pharmaceuticals Inc (Clementia) is a clinical stage biopharmaceutical company that focuses on the development of treatments for rare bone disorders and other diseases. Its lead product candidate Palovarotene is used for the treatment of fibrodysplasia ossificans progressiva (FOP), dry eye disease and multiple osteochondromas (MO). Palovarotene is a novel retinoic acid receptor gamma agonist, and an oral therapy that prevents the abnormal new bone formation as well as fibrosis in a variety of tissues. The company partners with pharmaceutical companies, universities and other research institutes to develop its product portfolio. It has presence in the US and Canada. Clementia is headquartered in Montreal, Quebec, Canada.

Clementia Pharmaceuticals Inc (CMTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Clementia Pharma Secures USD60 Million Venture Financing 12
Clementia Pharma Raises USD60 Million in Venture Financing 14
Clementia Pharma Raises USD8.5 Million in Extended Series A Venture Financing 16
Clementia Pharma Raises US$20.8 Million In Series A Financing 17
Partnerships 18
Clementia Pharma Enters into Agreement with Instituto Ortopedico Rizzoli 18
Licensing Agreements 19
Clementia Pharma Enters into Licensing Agreement with Galderma R&D 19
Clementia Pharma Enters Into License Agreement With Sanford Burnham Prebys Medical 20
Clementia Pharma Enters Into Licensing Agreement With Yamaguchi University 21
Clementia Pharma Enters into Licensing Agreement with Thomas Jefferson University 22
Clementia Pharma Enters into Licensing Agreement with F. Hoffmann-La Roche 23
Equity Offering 24
Clementia Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 24
Clementia Pharma Raises USD10 Million in Private Placement of Shares 26
Clementia Pharmaceuticals Inc – Key Competitors 27
Clementia Pharmaceuticals Inc – Key Employees 28
Clementia Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Clementia Pharmaceuticals announces second quarter 2018 financial results 30
May 09, 2018: Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates 31
Feb 28, 2018: Clementia Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results 32
Nov 13, 2017: Clementia Reports Third Quarter 2017 Financial Results and Business Highlights 33
Corporate Communications 34
Jul 13, 2018: Clementia Names Steve Forte As Chief Financial Officer 34
Jul 05, 2018: Clementia Names Shawn Tomasello Board Director 35
Jan 31, 2018: Clementia Appoints Pierre Legault As Board Director 36
Product News 37
06/05/2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children’s Bone Health 37
Clinical Trials 38
Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva 38
Nov 20, 2017: Preclinical study demonstrates promising treatment for rare bone disease 39
Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September 40
Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clementia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Clementia Pharma Secures USD60 Million Venture Financing 12
Clementia Pharma Raises USD60 Million in Venture Financing 14
Clementia Pharma Raises USD8.5 Million in Extended Series A Venture Financing 16
Clementia Pharma Raises US$20.8 Million In Series A Financing 17
Clementia Pharma Enters into Agreement with Instituto Ortopedico Rizzoli 18
Clementia Pharma Enters into Licensing Agreement with Galderma R&D 19
Clementia Pharma Enters Into License Agreement With Sanford Burnham Prebys Medical 20
Clementia Pharma Enters Into Licensing Agreement With Yamaguchi University 21
Clementia Pharma Enters into Licensing Agreement with Thomas Jefferson University 22
Clementia Pharma Enters into Licensing Agreement with F. Hoffmann-La Roche 23
Clementia Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 24
Clementia Pharma Raises USD10 Million in Private Placement of Shares 26
Clementia Pharmaceuticals Inc, Key Competitors 27
Clementia Pharmaceuticals Inc, Key Employees 28
Clementia Pharmaceuticals Inc, Subsidiaries 29

List of Figures
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Clementia Pharmaceuticals Inc (CMTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Xped Limited (XPE)-エネルギー分野:企業M&A・提携分析
    Summary Xped Limited (Xped) formerly Raya Group Limited, is an Internet of Things company that develops software and hardware solutions. It offers auto discovery remote control, Xerts, and Xped app software; and hardware such as Xped ADRC Shields, Umbo-Xped ADRC Hub, UltraPlug, VariPlug, IRBlaster. …
  • CP All Public Company Limited (CPALL):企業の財務・戦略的SWOT分析
    CP All Public Company Limited (CPALL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Metropolitan Bank and Trust Company:企業の戦略・SWOT・財務情報
    Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report Summary Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Tokio Marine Holdings, Inc.:企業の戦略・SWOT・財務情報
    Tokio Marine Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tokio Marine Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Nektar Therapeutics (NKTR):企業の財務・戦略的SWOT分析
    Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Medeon Biodesign Inc (6499):医療機器:M&Aディール及び事業提携情報
    Summary Medeon Biodesign Inc (Medeon Biodesign) is a medical device company that develops patient-centered medical device products that address unmet medical needs. The company’s products include cardiovascular devices and equipment, devices for minimally invasive surgeries, laparoscopic device, hig …
  • Emera (Caribbean) Inc.:企業の戦略的SWOT分析
    Emera (Caribbean) Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Siemens Ltd (SIEMENS):企業の財務・戦略的SWOT分析
    Siemens Ltd (SIEMENS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Vibra Healthcare LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Vibra Healthcare LLC (Vibra) is a healthcare service provider that provides short-term rehabilitation, long-term care, skilled nursing and respite care services. The organization develops and acquires medical rehabilitation hospitals and long term acute care hospitals. It offers services suc …
  • Exiqon AS:医療機器:M&Aディール及び事業提携情報
    Summary Exiqon AS (Exiqon), a subsidiary of Qiagen NV, is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company provides product categories such as microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reag …
  • CTI Engineering Co Ltd:企業の戦略・SWOT・財務情報
    CTI Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary CTI Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • BPCE SA:企業のM&A・事業提携・投資動向
    BPCE SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BPCE SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Dairy Crest Group plc:戦略・SWOT・企業財務分析
    Dairy Crest Group plc - Strategy, SWOT and Corporate Finance Report Summary Dairy Crest Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • ABPA Holdings Ltd:企業の戦略的SWOT分析
    ABPA Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • WorleyParsons Ltd (WOR):電力:M&Aディール及び事業提携情報
    Summary WorleyParsons Ltd (WorleyParsons) is a provider of professional services. Its services cover the full lifecycle, from creating new assets to sustaining and enhancing operating assets. The company provides integrated solution for deepwater developments with the associated subsea, pipelines, r …
  • Baptist Memorial Health Care Corp:企業の戦略的SWOT分析
    Baptist Memorial Health Care Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • MakeMusic, Inc.:企業の戦略的SWOT分析
    MakeMusic, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • ABF Ingredients Ltd:企業の戦略・SWOT・財務情報
    ABF Ingredients Ltd - Strategy, SWOT and Corporate Finance Report Summary ABF Ingredients Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Excelsior Medical Co Ltd (4104)-医療機器分野:企業M&A・提携分析
    Summary Excelsior Medical Co., Ltd. (Excelsior Medical), formerly Enfield Medical Co., Ltd. is a medical equipment manufacturer that develops and markets products for intraluminal catheter care. The company’s products include SwabCap, SwabFlush, SwabKIT, ZR syringes, flush syringes, PharmAssist and …
  • Strauss Group Ltd.:企業の戦略・SWOT・財務情報
    Strauss Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Strauss Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆